• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Tilray secures new cannabis cultivation license in Germany: Is it time to buy TLRY?

by July 22, 2024
written by July 22, 2024

Tilray Brands Inc (NASDAQ: TLRY) has made a significant stride in its European operations by securing a new cannabis cultivation license in Germany. 

This development, under the country’s new Cannabis Act (MedCanG), is set to substantially boost the production capacity of Tilray’s Aphria RX GmbH facility in Berlin. 

This news comes at a crucial time for the New York-based firm, which has seen its stock decline by 35% since early April.

What the new license means for Tilray stock

The new license is expected to increase Tilray’s production of medical cannabis by up to fivefold, according to the company’s press release on Monday. 

This expansion is a pivotal move for Tilray, potentially aiding in the recovery of its stock. The license also allows Tilray to cultivate and produce up to 31 approved strains of cannabis, a significant increase from the previous limit of three strains. 

This will not only enhance the genetic diversity of Tilray’s products but also expand its product range in Germany’s medical cannabis market.

Denise Faltischek, Tilray’s Chief Strategy Officer, highlighted the importance of the new license, stating it will enable “greater access to some of the highest quality medical cannabis produced in Germany.” 

This development underscores Tilray’s commitment to expanding its footprint in the European market and positions the company to capitalize on Germany’s growing medical cannabis industry.

Positive market response and strategic importance

Investors have responded positively to the news, with Tilray’s stock rising approximately 3% at the time of writing on Monday. 

This uptick reflects investor confidence in the company’s strategic moves to strengthen its presence in Europe and enhance its production capabilities.

The new license comes at a critical juncture for Tilray, as the company is set to report its second-quarter earnings on July 29th. 

The timing of this announcement could provide a much-needed boost in investor sentiment ahead of the earnings report. In 2019, the German Federal Institute for Drugs and Medical Devices (BfArM) granted Aphria RX the most comprehensive permit for the cultivation of medical cannabis. 

The new Cannabis Act has significantly increased the use of medical cannabis in Germany, and Tilray is now well-positioned to fully capitalize on this market opportunity with its new license.

Financial outlook and market expectations

Tilray’s recent financial performance has been mixed. The company broke even on a per-share basis in the fourth quarter of 2023 but is expected to report a loss of 2 cents per share in the upcoming fourth quarter.

Investors will be closely watching for updates on Tilray’s outlook for free cash flow, which management previously indicated is unlikely to turn positive in 2024.

Earlier in July, analysts at Zuanic & Associates assumed coverage of Tilray stock with a “neutral” rating.

They cited the company’s potential to benefit from regulatory updates in overseas medical markets as a key factor. This new license in Germany could be a catalyst for Tilray to leverage these regulatory changes and improve its financial performance.

Tilray’s acquisition of a new cannabis cultivation license in Germany marks a significant step in the company’s strategic expansion in Europe. 

The anticipated increase in production capacity and product diversity positions Tilray to capitalize on Germany’s growing medical cannabis market. 

As the company prepares to report its second-quarter earnings, this development could help restore investor confidence and pave the way for future growth.

Watch here: https://www.youtube.com/embed/0UUrKOz49MA?feature=oembed

The post Tilray secures new cannabis cultivation license in Germany: Is it time to buy TLRY? appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Vance hits campaign trail as Harris team scrambles to consolidate Dem support
next post
House GOP demands Secret Service director face accountability in new resolution: ‘Must be fired now’

related articles

Asian markets close: Nikkei, Kospi down; Sensex closes...

May 19, 2025

Qualcomm unveils AI chips for data centres with...

May 19, 2025

Best crypto to buy now: Bitcoin Pepe leads...

May 19, 2025

JPMorgan cuts Netflix rating, citing balanced risk-reward post-rally;...

May 19, 2025

Bitcoin ETF open interest dips 5% to $29.47B...

May 19, 2025

US stocks slip in the red on Monday:...

May 19, 2025

Should Klarna IPO remain on watch list after...

May 19, 2025

Why this brokerage downgraded UnitedHealth’s rating to ‘hold’

May 19, 2025

Nvidia opens NVLink Fusion ecosystem, expands Taiwan footprint...

May 19, 2025

Cathie Wood says Trump’s tariffs could unlock tech...

May 19, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Biden has signed just 2 executive orders since dropping out of 2024 race, trailing past presidents

    September 9, 2024
  • Trump’s tax overhaul hits GOP turbulence over Biden-era green incentives

    May 2, 2025
  • Trump pauses enforcement of law criminalizing foreign bribery: ‘In practicality, it’s a disaster’

    February 11, 2025
  • ‘Refuse to be their puppet’: Top 5 moments from Tulsi Gabbard’s confirmation hearing

    January 31, 2025
  • McDonald’s misses Q2 estimates as same-store sales decline for first time since pandemic

    July 30, 2024

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (4,735)
  • Investing (624)
  • Stock (775)

Latest Posts

  • Israeli ambassador slams UN’s ‘mafia-like’ tactics against US-backed Gaza foundation

    May 28, 2025
  • ‘What a ripoff!’: Trump sparks backlash after cutting billions in overhead costs from NIH research grants

    February 10, 2025
  • UN draft report on children in conflict zones raises eyebrows with framing of Israelis

    March 8, 2025

Recent Posts

  • The euro index is losing ground, the yen continues to rise

    August 26, 2024
  • FBI Director Christopher Wray announces resignation

    December 11, 2024
  • Harris supporters say keep some Biden policies, lose others amid reports she is seeking ‘distance’

    August 15, 2024

Editor’s Pick

  • UK government accused of cracking down on free speech: ‘Think before you post’

    September 14, 2024
  • Starbucks will stop charging extra for nondairy milk

    October 31, 2024
  • Biden administration pressuring African country to adopt lax abortion laws in exchange for foreign aid: report

    December 17, 2024
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock